Table 2.
Use of TLR agonists for lung cancer treatment.
| TLRs | TLR Agonists | Experimental Model/Clinical Trials | References |
|---|---|---|---|
| TLR2 | Pam2CSK4 | Mouse | (76) |
| TLR2 | CADI-05 | Combined with chemotherapy in trial patients | (77) |
| TLR2/4 | Polysaccharide | Lewis Lung Cancer (LLC)-bearing C57/BL6J mice and human NSCLC H460-bearing nude mice. | (78) |
| TLR3 | Poly I:C | LLC/2 tumor-bearing mice | (79) |
| TLR4 | Cucurbitacin B (CuB), | Mouse model (Cub, extracted from muskmelon pedicel, is a natural bioactive product) |
(35) |
| TLR4 | E. coli | C57BL/6 mice, promote metastasis | (80) |
| TLR4 | L6H21 (an MD2 inhibitor) | Prevents lung metastasis in CT26 mouse model | (81) |
| TLR5 | CBLB502 | Nude mice (enhances radiosensitivity) | (59) |
| TLR7 | TQ-A3334 | Phase II Trial | (82) |
| TLR7 | BNT411 | Phase II Trial | (83) |
| TLR7/8 | R848 | C57BL/6 mice | (37) |
| TLR7/8 | BDB001 | Phase II trial in patients with PD-(L)1 refractory solid tumors, including NSCLC | (84) |
| TLR9 | MGN1703 | Phase II Trial | (27) |
| TLR9 | IMO-2055 | Combined with chemotherapy in Phase II trial | (85) |
| TLR9 | PF-3512676 | Combined with chemotherapy in Phase III trial (*last updated in 2015, but no study results are posted on clinicaltrials.gov) | (86) |